What's New

The global response in the last 15 years has recorded unparalleled progress in its fight against HIV/AIDS. Since 2000, new infections in adults and children have declined 35%, death from HIV-related causes has declined 24%, almost 16 million people living with HIV are now on ART, and the global response has averted 30 million new HIV infections and 7.8 million AIDS-related deaths. However, despite these achievements, significant challenges remain. An ambitious goal of ending the AIDS epidemic by 2030 has been set by the international community and rapid progress is required in the coming years to render such a goal feasible. In the next five years, three fast-track targets have been established to enable reaching such goal: 1) 90% of PLHIV know their status by 2020; 2) 90% of people diagnosed with HIV receive ART by 2020; and 3) 90% of the people receiving treatment achieve viral suppression by 2020. It is estimated that meeting these “90-90-90 fast-track targets” will avert 28 million HIV infections and 21 million AIDS-related deaths by 2030. In order to reach these targets, it is imperative to scale-up access to innovative cost-effective tools for HIV prevention, testing, treatment, and monitoring.

The field of HCV therapeutics continues to evolve rapidly and, since the World Health Organization (WHO) issued its first Guidelines for the screening, care and treatment of persons with hepatitis C infection in 2014, several new medicines have been approved by at least one stringent regulatory authority. These medicines, called direct-acting antivirals (DAAs), are transforming the treatment of HCV, enabling regimens that can be administered orally, are of shorter duration (as short as eight weeks), result in cure rates higher than 90%, and are associated with fewer serious adverse events than the previous interferon- containing regimens. WHO is updating its hepatitis C treatment guidelines to provide recommendations for the use of these new medicines. The objectives of these WHO guidelines are to provide updated evidence- based recommendations for the treatment of persons with hepatitis C infection using, where possible, all DAA-only combinations. The guidelines also provide recommendations on the preferred regimens based on a patient’s HCV genotype and clinical history, and assess the appropriateness of continued use of certain medicines. This document also includes existing recommendations on screening for HCV infection and care of persons infected with HCV that were first issued in 2014. 

This preliminary report presents provisional results on the availability and preparedness of health facilities to provide maternal and child health, family planning, and other services based on information collected from the different types of health facilities. This information will help health program managers and policy makers prioritize interventions that will enhance the provision of quality health services. A comprehensive report on the survey findings will be published later in 2016. The data in the final report are not expected to differ substantially from the findings presented in this preliminary report; however, the results presented here should be regarded as provisional and may be subject to change.

The enactment and enforcement of HIV-specific criminal laws – or even the threat of their enforcement – fuels the fires of stigma. It reinforces the idea that HIV is shameful, that it is a disgraceful contamination. And by reinforcing stigma, HIV criminalisation makes it more difficult for those at risk of HIV to access testing and prevention. It also makes it more difficult for those living with the virus to talk openly about it, and to be tested, treated and supported. The Advancing HIV Justice reports show how far we have come. This second iteration of these important progress reports documents how the movement against these laws and prosecutions – burgeoning just a decade ago – is gaining strength. It is achieving some heartening outcomes. Laws have been repealed, modernised or struck down across the globe – from Australia to the United States, Kenya to Switzerland.

In April 2016, there were 772 new HIV Ab seropositive individuals reported to the HIV/AIDS & ART Registry of the Philippines. This was 38% higher compared to the same period last year (560) [Figure 1]. Eighty-four percent of the cases were asymptomatic at the time of reporting. Most (94%) were male. The median age was 28 years old (age range: 7 years-65 years). More than half belong to the 25-34 year age group while 29% were youth aged 15-24 years.

Through this guide, Unzip the Lips aims to promote the engagement of Key Affected Women and Girls, (KAWG) community networks and NGOs with the Universal Periodic Review (UPR) process. The goal is to strengthen advocacy for the needs and rights of these groups, and to ensure that their sexual and reproductive health and rights are respected, protected and fulfilled. In this guide, you will learn about the role of the UPR process in advancing sexual and reproductive health and rights. You will also learn about why and how to engage with this important human rights review mechanism. This guide provides concrete information regarding State obligations under the UPR process; it also explains your rights and how to claim them at a national level. 

Global Consultation on the Programmatic Management of Latent Tuberculosis Infection Date: 27-28 April 2016 Venue: Hotel President, Seoul, Republic of Korea

Get an overview of the HIV/AIDS situation for Women and Men in the Asia-Pacific region. Browse and view tables, charts and graphs illustrating data on HIV prevalence and epidemiology, risk behaviors, national response and data issues for this key population.

The Global TB Programme of WHO in collaboration with the Republic of Korea’s Centers for Disease Control and Prevention and International Tuberculosis Research Center organized a global consultation on the management of latent tuberculosis infection (LTBI) that was held during April 27–28, 2016, in Seoul, Republic of Korea. The objective of the meeting was to present and discuss challenges to, opportunities for, and best practices on the programmatic management of LTBI, and to consider recommendations to facilitate its implementation in both high-burden and low-burden countries.

Heads of State and Government and representatives of States and Governments assembled at the United Nations from 8 to 10 June 2016, reaffirm the commitment to end the AIDS epidemic by 2030 as the legacy to present and future generations, to ensure that we are on the Fast-Track to reach this target, and to seize the new opportunities provided by the 2030 Agenda for Sustainable Development to accelerate action and to recast our approach to AIDS given the potential of SDGs to accelerate joined-up and sustainable efforts to lead to the end of AIDS and we pledge to intensify efforts that will help to increase the life expectancy, quality of life, and dignity of all people living with, at risk of and affected by HIV.